#USA #Tampa #Concept Medical #Sirolimus #PAD

Concept Medical's Positive SIRONA Trial Results

On January 8, 2025, Concept Medical Inc., a leader in drug delivery technology, announced impressive findings from its randomized clinical trial known as SIRONA. This trial, titled "Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting Balloon Angioplasty in the Femoropopliteal Artery," presents evidence that the sirolimus-coated balloon (SCB), branded as MagicTouch PTA, may provide comparable patency and functional benefits as traditional paclitaxel-coated balloons in patients suffering from peripheral artery disease (PAD).

Key Findings of the SIRONA Trial

The SIRONA trial involved 482 patients recruited from 25 sites across Germany and Austria. The primary focus was to compare the performance of the MagicTouch PTA against seven commercially available paclitaxel-coated balloons. The trial's results include:

1. Primary Patency Rates: At one year, the MagicTouch PTA achieved a primary patency rate of 73.8%, compared to 75.0% for the paclitaxel group, establishing non-inferiority in efficacy.
2. Safety Profile: The trial indicated no significant differences in clinically driven target lesion revascularization (cdTLR) rates at 12 months, showing 92.9% for MagicTouch PTA versus 95.4% for the paclitaxel group.
3. Functional Improvements: Both treatment groups exhibited similar improvements in functional outcomes, with 89% of patients experiencing at least a one-stage improvement on the Rutherford scale.

The principal investigator, Professor Ulf Teichgräber, presented these findings at the TCT USA 2024 conference, emphasizing the potential of sirolimus-based therapy as a viable alternative in femoropopliteal interventions. Notably, the study highlighted that, while paclitaxel-based therapies have been the standard treatment, emerging safety concerns necessitate exploring alternatives like sirolimus.

Implications for Clinical Practice

Professor Dierk Scheinert, a supporter of the SIRONA trial, noted that the results represent a significant milestone, providing Level 1 evidence of the clinical efficacy of MagicTouch PTA for a wide range of femoropopliteal blockages. This opens the doors for medical professionals to personalize treatment approaches for PAD patients more effectively.

Dr. Manish Doshi, founder and CEO of Concept Medical, expressed the company's commitment to innovation in vascular therapy. He stated, "The SIRONA study results empower us to fulfill our mission of delivering patient-centered, evidence-based solutions aimed at enhancing care and outcomes for individuals suffering from peripheral artery disease."

About Concept Medical

Headquartered in Tampa, Florida, Concept Medical is at the forefront of drug delivery systems for medical treatments. Its flagship product, the MagicTouch Sirolimus Coated Balloon (SCB), has transformed the landscape of both coronary and peripheral interventions, benefiting over a million patients globally. The company remains dedicated to rigorous clinical research, exemplified by the SIRONA study, and continues to lead the development of next-generation vascular therapies.

For further details on the SIRONA trial and Concept Medical's innovative product portfolio, visit Concept Medical's website.